Vemurafenib-associated Dupuytren- and Ledderhose palmoplantar fibromatosis in metastatic melanoma patients.
J Eur Acad Dermatol Venereol
; 30(7): 1133-5, 2016 Jul.
Article
en En
| MEDLINE
| ID: mdl-26303964
ABSTRACT
BACKGROUND:
The BRAF-inhibitor vemurafenib, used in patients with metastatic melanoma, induces multiple cutaneous side-effects.OBJECTIVE:
The aim of this work was to evaluate the development of palmoplantar fibromatosis in a population of patients treated with the BRAF inhibitor vemurafenib.METHODS:
Between April 2011 and February 2013, we initiated a treatment with vemurafenib in 53 patients with an unresectable stage IIIC or stage IV melanoma. The patients were followed-up on a regular base to monitor possible side-effects.RESULTS:
A plantar or palmar fibromatosis was observed in five of 53 patients treated with vemurafenib. In four of these patients other risk factors for the development of palmoplantar fibromatosis were absent.CONCLUSION:
The BRAF-inhibitor vemurafenib might induce palmoplantar fibromatosis.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Sulfonamidas
/
Contractura de Dupuytren
/
Pie
/
Indoles
/
Melanoma
Tipo de estudio:
Risk_factors_studies
Límite:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
J Eur Acad Dermatol Venereol
Asunto de la revista:
DERMATOLOGIA
/
DOENCAS SEXUALMENTE TRANSMISSIVEIS
Año:
2016
Tipo del documento:
Article
País de afiliación:
Bélgica